Table 4 Drugs most frequently occurring in intervention reports and their potential risk
From: Drug-related problems and their clinical interventions in a Ghanaian teaching hospital
Drug | Number in reports, n (%) | Examples of potential risk | Outcome of intervention | |
|---|---|---|---|---|
Accepted | Not accepted | |||
Warfarin | 97 (9.5) | Bleeding | 89 | 8 |
Slow K | 61 (6.0) | Electrolyte imbalance | 56 | 5 |
Gentamicin | 60 (5.9) | Tinnitus | 45 | 15 |
Potassium Citrate | 56 (5.5) | Electrolyte imbalance | 41 | 15 |
Enoxaparin | 55 (5.4) | DVT | 46 | 9 |
Diclofenac | 43 (4.2) | Gastrointestinal bleeding | 40 | 3 |
Heparin | 39 (3.8) | Bleeding | 34 | 5 |
Morphine | 38 (3.7) | Respiratory depression | 35 | 3 |
Frusemide | 37 (3.6) | Electrolyte imbalance | 29 | 8 |
Iron Supplement | 37 (3.6) | Anaemia | 34 | 3 |
Clindamycin | 27 (2.6) | Diarrhoea | 25 | 2 |
Metolazone | 26 (2.6) | Electrolyte imbalance | 26 | 0 |
Omeprazole | 24 (2.4) | Gastrointestinal bleeding | 21 | 3 |
Atenolol | 20 (2) | Heart block | 19 | 1 |
Hydrochlorthiazide | 18 (1.8) | Electrolyte imbalance | 18 | 0 |
Metronidazole | 16 (1.6) | Increased hospital cost | 14 | 2 |
Rosuvastatin | 15 (1.5) | Cardiovascular event | 15 | 0 |
Cefuroxime | 13 (1.3) | Severe diarrhoea | 13 | 0 |
Ciprofloxacin | 13 (1.3) | Muscle weakness | 13 | 0 |
Lisinopril | 13 (1.3) | Neonatal mortality | 11 | 2 |